<qa>  What is the first anti-angiogenic drug approved in solid tumors?Angiogenesis, the development of new blood vessels, plays an important role in the disease development and tumor growth in many solid organ malignancies. Bevacizumab was the first anti-angiogenic drug to be approved in solid tumors and has shown advantageous activity with multiple tumor types. However, the responses from Bevacizumab are often transient due to the tumors manipulative abilities to circumvent the usual pathways to find salvage pathways instead. 